Structure via PubChem · Public domain (PubChem)
alpelisib
Sign in to saveAlso known as BYL719, BYL 719, BYL-719, NVP-BYL719
Alpelisib, sold under the brand name Piqray among others, is a medication used to treat certain types of breast cancer. It is used together with fulvestrant. It is taken by mouth. It is marketed by Novartis.
Chemical data
- Formula
- C19H22F3N5O2S
- Molecular weight
- 441.5 g/mol
- IUPAC name
- (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
- SMILES
- CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
- InChIKey
- STUWGJZDJHPWGZ-LBPRGKRZSA-N
- XLogP
- 3.2
- Polar surface area
- 129 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2019
- Admin. routes
- oral
- Indications
- breast carcinoma, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 441.145
Show 5 more facts
- canonical SMILES
- CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
- chemical formula
- C₁₉H₂₂F₃N₅O₂S
- isomeric SMILES
- CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
- World Health Organisation international non-proprietary name
- alpelisib
- medical condition treated
- breast cancer
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- References
- External links
Alpelisib, sold under the brand name Piqray among others, is a medication used to treat certain types of breast cancer. It is used together with fulvestrant. It is taken by mouth. It is marketed by Novartis.
Common side effects include high blood sugar, kidney problems, diarrhea, rash, low blood cells, liver problems, pancreatitis, vomiting, and hair loss. It is an alpha-specific PI3K inhibitor. It was approved for medical use in the United States in May 2019.
Excerpted from Wikipedia’s “alpelisib” article, available under the CC BY-SA 4.0 licence.